The emerging market for long-term nicotine maintenance

JAMA

Volumn 278, Issue 13, 1997, Pages 1087-1092

  Warner, Kenneth E ^a,d   Slade, John ^b   Sweanor, David T ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c Non Smokers' Rights Association   (Canada)

^d UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; NICOTINE GUM;

ADDICTION; DRUG INDUSTRY; MARKET; PRIORITY JOURNAL; REVIEW; SMOKING; UNITED STATES;

EID: 0030876369     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.13.1087     Document Type: Review

References (61)

1. McGinnis JM, Foege WH. Actual causes of death in the United States. JAMA. 1993;270:2207-2212.
2. US Dept of Health and Human Services. The Health Consequences of Smoking: Nicotine Addiction: A Report of the Surgeon General. Washington, DC: US Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health; 1988. US Dept of Health and Human Services publication (CDC) 88-8406.
3. US Dept of Health and Human Services. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. Washington, DC: US Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1990. US Dept of Health and Human Services publication (CDC) 90-8416.
4. Russell MAH. The future of nicotine replacement. Br J Addiction. 1991;86:653-658.
5. Hughes JR. Applying harm reduction to smoking. Tob Control. 1995;4(suppl 2):S33-S38.
6. Tobacco or Health Programme, World Health Organization. Guidelines for Controlling and Monitoring the Tobacco Epidemic. Geneva, Switzerland: World Health Organization. In press.
7. West R, Grunberg NE. Implications of tobacco use as an addiction. Br J Addiction. 1991;86:485-488.
8. Jimenez-Ruiz C, Kunze M, Fagerstrom KO. Nicotine Replacement: A New Approach to Reduce Tobacco-Related Harm. Helsingborg, Sweden: Dept of Pulmonary Medicine, Helsingborg Hospital; 1997. Working paper.
9. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997;29:1422-1431.
10. Heishman SJ, Taylor RC, Henningfield JE. Nicotine and smoking: a review of the effects on human performance. Exp Clin Psychopharmacol. 1994;2:345-395.
11. Heishman SJ, Taylor RC, Henningfield JE. Performance, subjective, and physiological effects of nicotine in nonsmokers. Drug Alcohol Depend. 1993; 34:11-18.
12. Eliasson B, Taskinen M-R, Smith U. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. Circulation. 1996;94: 878-881.
13. Davis RM, Slade J. Back to the future - with electrically powered cigarettes. Tob Control. 1993; 2:11-12.
14. The Smoking Cessation Clinical Guideline Panel and Staff. The Agency for Health Care Policy and Research Smoking Cessation Clinical Practice Guideline. JAMA. 1996;275:1270-1280.
15. Jarvik ME, Henningfield JE. Pharmacological adjuncts for the treatment of nicotine dependence. In: Orleans CT, Slade J, eds. Nicotine Addiction: Principles and Management. New York, NY: Oxford University Press; 1993:245-261.
16. Chemical and Biological Studies of New Cigarette Prototypes That Heat Instead of Burn Tobacco. Winston-Salem, NC: R.J. Reynolds Tobacco Co; 1988.
17. Pauly JL, Streck RJ, Cummings KM. US patents shed light on Eclipse and future cigarettes. Tob Control. 1995;4:261-265.
18. Hilts PJ. Less smoke and less tar, but full dose of nicotine. New York Times. November 27, 1994:1, 13.
19. Jamieson S. Nicotine inhaler that mimics smoking clears FDA panel. Charlotte Observer. March 17, 1997:1E.
20. Leischow SJ, Nilsson F, Franzon M, Hill A, Otte P, Merikle IP. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. Am J Health Behav. 1996;20:364-371.
21. Smith CJ, McKarns SC, Davis RA, et al. Human urine mutagenicity study comparing cigarettes which burn or primarily heat tobacco. Mutat Res. 1996;361:1-9.
22. Steimle S. Smokeless cigarettes not harmless, researchers say. J Natl Cancer Inst. 1996;88:1341-1343.
23. US Dept of Health and Human Services. Reducing the Health Consequences of Smoking: 25 Years of Progress: A Report of the Surgeon General. Washington, DC: US Public Health Service, Centers for Disease Control, Center for Chronic Di-ease Prevention and Health Promotion, Office on Smoking and Health; 1989. US Dept of Health and Human Services publication (CDC) 89-8411.
24. Slade J. The tobacco epidemic: lessons from history. J Psychoactive Drugs. 1989;21:281-291.
25. Broder K. New generation cigarettes: safety or smoke screen? J Natl Cancer Inst. 1990;82:89-91.
26. Kluger R. Ashes to Ashes: America's Hundred-Year Cigarette War, the Public Health, and the Unabashed Triumph of Philip Morris. New York, NY: Alfred A Knopf; 1996.
27. Longo WE, Rigler MW, Slade J. Crocidolite asbestos fibers in smoke from original Kent cigarettes. Cancer Res. 1995;55:2232-2235.
28. Slade J. Nicotine delivery devices. In: Orleans CT, Slade J, eds. Nicotine Addiction: Principles and Management. New York, NY: Oxford University Press; 1993:3-23.
29. Davis RM. Current trends in cigarette advertising and marketing. N Engl J Med. 1987;316:725-732.
30. Holbrook J. Tobacco smoking. In: Petersdorf RG, ed. Harrison's Principles of Internal Medicine. 10th ed. New York, NY: McGraw-Hill; 1983:1303-1305.
31. Willner JS. Tobacco abuse and dependence. In: Taylor RB, ed. Family Medicine. 2nd ed. New York, NY: Springer-Verlag; 1983:1662-1665.
32. Kozlowski LT, Pillitteri JL. Compensation for nicotine by smokers of lower yield cigarettes. In: US Dept of Health and Human Services. The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of U.S. Cigarettes: Report of the NCI Expert Committee. Bethesda, MD: National Cancer Institute; August 1996:161-172. National Institutes of Health publication 96-4028.
33. Henningfield JE, Schuh LM. Pharmacology and markers: nicotine pharmacology and addictive effects. In: US Dept of Health and Human Services. The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of U.S. Cigarettes: Report of the NCI Expert Committee. Bethesda, Md: National Cancer Institute; August 1996:113-126. National Institutes of Health publication 96-4028.
34. Benowitz NL. Biomarkers of cigarette smoking. In: US Dept of Health and Human Services. The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of U.S. Cigarettes: Report of the NCI Expert Committee. Bethesda, Md: National Cancer Institute; August 1996:93-111. National Institutes of Health publication 96-4028.
35. US Dept of Health and Human Services. The FTC Cigarette Test Method far Determining Tar, Nicotine, and Carbon Monoxide Yields of U.S. Cigarettes: Report of the NCI Expert Committee. Bethesda, Md: National Cancer Institute; August 1996. National Institutes of Health publication 96-4028.
36. Harris JE. A working model for predicting the consumption and revenue impacts of large increases in the U.S. federal cigarette excise tax. Cambridge, Mass: National Bureau of Economic Research; July 1994. NBER Working Paper 4803.
37. Giovino GA, Tomar SL, Reddy MN, et al. Attitudes, knowledge, and beliefs about low-yield cigarettes among adolescents and adults. In: US Dept of Health and Human Services. The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of U.S. Cigarettes: Report of the NCI Expert Committee. Bethesda, Md: National Cancer Institute; August 1996:39-57. National Institutes of Health publication 96-4028.
38. Glantz SA, Slade J, Bero LA, Hanauer P, Barnes DE. The Cigarette Papers. Berkeley: University of California Press; 1996.
39. Response of the market and of Imperial Tobacco to the smoking and health environment. Document from the files of Imperial Tobacco, Ltd, Montreal, Quebec, 1978. Exhibit AG-41 in RJR Macdonald, Inc. and Imperial Tobacco, Ltd. v The Attorney General of Canada. Montreal, Quebec: Superior Court; 1989.
40. Canadian Facts. Project Eli. Report prepared for Imperial Tobacco, Ltd, Montreal, Quebec, Spring 1982. Exhibit AG-42 in RJR Macdonald, Inc. and Imperial Tobacco, Ltd. v The Attorney General of Canada. Montreal, Quebec: Superior Court; 1989.
41. Schwartz J, Torry S. Tobacco pact calls for strict federal controls. Washington Post. June 21, 1997:A1.
42. Brownson RC, Eriksen MP, Davis RM, Warner KE. Environmental tobacco smoke: health effects and policies to reduce exposure. Annu Rev Public Health. 1997;18:163-185.
43. Leischow SJ, Stine CM, Nordbrock J, Marriott J, Zobrist RH. One week trial of oral transmucosal nicotine for smoking cessation. J Addict Dis. 1996; 15:146. Abstract.
44. Puska P, Korhonen HJ, Vartiainen E, Urjanheirao E-L, Gustavsson G, Westin A. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tob Control. 1995;4:231-235.
45. Oster G, Delea TE, Huse DM, Regan MM, Colditz GA. The benefits and risks of over-the-counter availability of nicotine polacrilex ('nicotine gum'). Med Care. 1996;34:389-102.
46. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3094 participants in the Lung Health Study. Chest. 1996;109:438-445.
47. Hwang SL. Drug makers use slick TV ads to get people to quit smoking. Wall Street Journal. May 21, 1996.
48. Wilke M. NicoDerm CQ lighting $35 mil in nicotine patch skirmish. Advertising Age. August 19, 1996:10.
49. US Dept of Health and Human Services Food and Drug Administration. Regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents; final rule. Federal Register. August 28, 1996;61(168): 44396-45318.
50. Coyne Beahm, Inc. v FDA. Civ. No. 95CV00591 (M.D.N.C. April 25, 1997).
51. ASH uses legal action to attack 'Eclipse' a bogus dangerous 'smokeless cigarette.' ASH Smoking Health Rev. May-June 1996:2.
52. Benowitz NL, Henningfield JE. Establishing a nicotine threshold for addiction. N Engl J Med. 1994; 331:123-125.
53. Campbell WI. Testimony at hearings before the Subcommittee on Health and the Environment of the Committee on Energy and Commerce. In: Regulation of Tobacco Products. Washington, DC: US House of Representatives, Serial No. 103-149; April 14, 1994:542-546.
54. Cunningham R, Kyle K. The case for plain packaging. Tob Control. 1995;4:80-86.
55. Mahood G. Canadian tobacco package warning system. Tob Control. 1995;4:10-14.
56. Gori GB, Lynch CJ. Toward less hazardous cigarettes: current advances. JAMA. 1978;240:1255-1259.
57. Rodu B. For Smokers Only: How Smokeless Tobacco Can Save Your Life. New York, NY: Sulzberger & Graham; 1995.
58. Tomar SL. Smokeless tobacco: a life saver? Tob Control. 1996;5:77-78.
59. Russell MAH. Low-tar medium-nicotine cigarettes: a new approach to safer smoking. BMJ. 1976; 1:1430-1433.
60. Slade J, Connolly GN, Davis RM, et al. Report of the tobacco policy research study group on adjunctive medications for managing nicotine dependence. Tob Control. 1992;1(suppl):S10-S13.
61. Hilts PJ. Smoke Screen: the Truth Behind the Tobacco Industry Cover-up. Reading, Mass: Addison-Wesley; 1996.